Literature DB >> 27019967

Calculated Log D Is Inversely Correlated With Select Camptothecin Clearance and Efficacy in Colon Cancer Xenografts.

Charvi Nanavati1, Donald E Mager2.   

Abstract

Quantitative structure-property relationships are often derived to identify molecular determinants of drug potency and facilitate drug design. However, compound activity is typically based on in vitro bioassays, and the influence of physicochemical properties on pharmacokinetic/pharmacodynamic (PK/PD) behavior is not considered. Here, we integrate PK/PD and quantitative structure-property relationship modeling to evaluate the role of lipophilicity in camptothecin antitumor responses in colon cancer xenografts. Drug exposure and tumor growth profiles for 5 camptothecins were extracted from the literature. A PK/PD model with time-dependent transduction was developed, which characterized PK and tumor growth inhibition. Correlations between drug lipophilicity (log D), in vitro potency (IC50), and in vivo efficacy and systemic clearance parameters were tested. Models were qualified using leave-one-out cross-validation. Efficacy and clearance of analogs decreased linearly with increasing log D values; efficacy exhibiting a steeper decline relative to clearance. Cross-validated R(2) for predicting in vivo efficacy was 0.55 and 0.18 using log D and in vitro IC50 as the descriptors. Lipophilicity may represent a better predictor of in vivo efficacy than in vitro IC50 measurements for camptothecins. The identified relationships between efficacy, clearance, and lipohilicity may help guide development of new camptothecin analogs and delivery systems with improved pharmacologic profiles.
Copyright © 2016 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  camptothecin; lipophilicity; pharmacokinetic–pharmacodynamic modeling; quantitative structure–property relationships; tumor growth

Mesh:

Substances:

Year:  2016        PMID: 27019967      PMCID: PMC4813326          DOI: 10.1016/j.xphs.2016.01.026

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  22 in total

1.  Quantitative structure-pharmacokinetic/pharmacodynamic relationships of corticosteroids in man.

Authors:  Donald E Mager; William J Jusko
Journal:  J Pharm Sci       Date:  2002-11       Impact factor: 3.534

2.  Efficacy and toxicity profile of oral topotecan in a panel of human tumour xenografts.

Authors:  M De Cesare; F Zunino; S Pace; C Pisano; G Pratesi
Journal:  Eur J Cancer       Date:  2000-08       Impact factor: 9.162

Review 3.  Quantitative structure-pharmacokinetic/pharmacodynamic relationships.

Authors:  Donald E Mager
Journal:  Adv Drug Deliv Rev       Date:  2006-09-19       Impact factor: 15.470

4.  Relationship between plasma exposure of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite and antitumor response in mice bearing human colon carcinoma xenografts.

Authors:  William C Zamboni; Laura L Jung; Merrill J Egorin; Deborah R Hamburger; Erin Joseph; Ruzhi Jin; Sandra Strychor; Ramesh K Ramanathan; Julie L Eiseman
Journal:  Clin Cancer Res       Date:  2005-07-01       Impact factor: 12.531

5.  Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin.

Authors:  Y H Hsiang; M G Lihou; L F Liu
Journal:  Cancer Res       Date:  1989-09-15       Impact factor: 12.701

6.  Pharmacodynamic modeling of chemotherapeutic effects: application of a transit compartment model to characterize methotrexate effects in vitro.

Authors:  Evelyn D Lobo; Joseph P Balthasar
Journal:  AAPS PharmSci       Date:  2002

7.  Hydrophilic camptothecin analogs that form extremely stable cleavable complexes with DNA and topoisomerase I.

Authors:  Randy M Wadkins; David Bearss; Govindarajan Manikumar; Mansukhlal C Wani; Monroe E Wall; Daniel D Von Hoff
Journal:  Cancer Res       Date:  2004-09-15       Impact factor: 12.701

8.  Topoisomerase I-DNA complex stability induced by camptothecins and its role in drug activity.

Authors:  Randy M Wadkins; David Bearss; Govindarajan Manikumar; Mansukhlal C Wani; Monroe E Wall; Daniel D Von Hoff
Journal:  Curr Med Chem Anticancer Agents       Date:  2004-07

9.  Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin.

Authors:  Y H Hsiang; L F Liu
Journal:  Cancer Res       Date:  1988-04-01       Impact factor: 12.701

Review 10.  Camptothecin: current perspectives.

Authors:  Craig J Thomas; Nicolas J Rahier; Sidney M Hecht
Journal:  Bioorg Med Chem       Date:  2004-04-01       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.